Track Arbutus Biopharma Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Arbutus Biopharma Corporation ABUS · Stock Open Arbutus Biopharma Corporation in new tab

4.36 USD
Add to portfolio
P/E
5.25
EPS
0.83
P/B
3.30
ROE
94.73
Beta
0.60
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 5, 2026
P/E5.25
EPS0.83
Book Value1.32
Price to Book3.30
Debt/Equity1.50
% Insiders20.459%
Growth
Revenue Growth100.55%
Estimates
Forward P/E-26.38
Forward EPS-0.17

DCF Valuation

Tweak assumptions to recompute fair value for Arbutus Biopharma Corporation (ABUS)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Arbutus Biopharma Corporation Logo Arbutus Biopharma Corporation Analysis (ABUS)

United States Health Care Official Website Stock

Is Arbutus Biopharma Corporation a good investment? Arbutus Biopharma Corporation (ABUS) is currently trading at 4.36 USD.

In terms of valuation, the stock trades at a P/E ratio of 5.25. This relatively low multiple may signal that Arbutus Biopharma Corporation is undervalued compared to historical market norms.

Earnings Schedule: Arbutus Biopharma Corporation is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -0.17.

Investor FAQ

Does Arbutus Biopharma Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Arbutus Biopharma Corporation?

Arbutus Biopharma Corporation is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of 0.83.

Company Profile

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.

Exchange Ticker
FRA (Germany) I9DN.F
LSE (United Kingdom) 0SGC.L
NMS (United States) ABUS
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 4, 2010 0.200000
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion